Employee Benefit Plan Consulting, Actuarial and Brokerage

Drug prices going up despite Administration’s promise

Sep 25, 2018

Rx costs continue to climb, despite talk from the Administration about setting cost controls, despite outcries over EpiPen costs, despite Pfizer and Nostrum Laboratories raising prices from 10% to 404%. We have a broken pricing system that will only cost us more and more until, as a country, we demand controls be set.Read full article here

Have a Question About Employee Benefits for Your Company?

Armstrong, Doyle & Caroll has served the greater Philadelphia area for over 65 years.